Company: BDRX
Filing Date: 2025-01-17
Form Type: F-1
Source: 0001214659-25-000922
Chunk: 374

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-01-17
Form: F-1
Chunk 374
---
 initially recognised at fair value net of any transaction costs directly attributable to the issue of the instrument.     
 Such interest-bearing liabilities are subsequently measured at amortised cost using the effective interest rate method, which ensures    
 that any interest expense over the period to repayment is at a constant rate on the balance of the liability carried in the consolidated 
 statement of financial position. Interest expense in this context includes initial transaction costs and premium payable on redemption,  
 as well as any interest or coupon payable while the liability is outstanding.                                                            |

| · | Government loans received on favourable terms below market rate are discounted at a market rate of interest. The difference between              
 the present value of the loan and the proceeds is held as a government grant within deferred revenue and is released to research and development 
 expenditure or grant income in line with when the asset or expenditure is recognised in the income statement.                                    |

| · | Trade payables and other short-term monetary liabilities are initially recognised at fair value and subsequently carried at amortised 
 cost using the effective interest method.                                                                                             |

Share capital

Financial instruments
issued by the Group are classified as equity only to the extent that they do not meet the definition of a financial liability or financial
asset. The Group has three classes of share in existence:

| · | ordinary shares of £0.001 each are classified as equity instruments; |

| · | ‘A’ deferred shares of £1 each are classified as equity instruments; |

| · | ‘B’ deferred shares of £0.001 each are classified as equity instruments. |

Retirement benefits: defined contribution schemes

Contributions to defined
contribution pension schemes are charged to the consolidated statement of comprehensive income in the year to which they relate.

Provisions

Provisions are recognised
when the Group has a present obligation (legal or constructive) as a result of a past event; it is probable that an outflow of resources
embodying economic benefits will be required to settle the obligation and a reliable estimate can be made of the amount of the obligation.

Share-based payments

The Group operates a
number of equity-settled, share-based compensation plans, under which the entity receives services from employees as consideration for
equity instruments (options) of the Group. The fair value of the employee services received in exchange for the grant of the options is
recognised as an expense. The total amount to be expensed is determined by reference to the fair value of the options granted:

| · | including any market performance conditions (including the share price); |